Ceranapril and cerebral blood flow autoregulation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Ceranapril and cerebral blood flow autoregulation. / Torup, M; Waldemar, G; Paulson, O B.
I: Journal of Hypertension, Bind 11, Nr. 4, 04.1993, s. 399-405.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Ceranapril and cerebral blood flow autoregulation
AU - Torup, M
AU - Waldemar, G
AU - Paulson, O B
PY - 1993/4
Y1 - 1993/4
N2 - OBJECTIVE: To investigate the effect of the new angiotensin converting enzyme inhibitor ceranapril (1 mg/kg) on the cerebral blood flow (CBF) autoregulation in normotensive Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR).DESIGN: Sixteen WKY rats and 16 SHR were given ceranapril 1 mg/ml intravenously and compared with two untreated control groups (n = 16). The rats were furthermore divided into subgroups of eight to study the upper and lower limits of autoregulation separately.METHODS: CBF was measured using the intracarotid xenon-133 injection technique. The arterial blood pressure was raised stepwise by noradrenaline or lowered stepwise by controlled bleeding, in order to study CBF over a range of mean arterial pressure (MAP) values.RESULTS: Baseline MAP was significantly lower in the WKY rat group than in the SHR group. There was no significant difference in baseline CBF between the treated and the untreated groups. Following ceranapril administration, baseline MAP was reduced by 10 mmHg in WKY rats and by 20 mmHg in SHR, and the limits of CBF autoregulation were reset at lower blood pressure levels. In WKY rats as well as in SHR, ceranapril significantly reduced the lower blood pressure limit of CBF autoregulation. In both strains the upper limit of CBF autoregulation was reduced significantly.CONCLUSION: Ceranapril preserves CBF autoregulation and significantly shifts the limits of CBF autoregulation towards lower blood pressure values.
AB - OBJECTIVE: To investigate the effect of the new angiotensin converting enzyme inhibitor ceranapril (1 mg/kg) on the cerebral blood flow (CBF) autoregulation in normotensive Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR).DESIGN: Sixteen WKY rats and 16 SHR were given ceranapril 1 mg/ml intravenously and compared with two untreated control groups (n = 16). The rats were furthermore divided into subgroups of eight to study the upper and lower limits of autoregulation separately.METHODS: CBF was measured using the intracarotid xenon-133 injection technique. The arterial blood pressure was raised stepwise by noradrenaline or lowered stepwise by controlled bleeding, in order to study CBF over a range of mean arterial pressure (MAP) values.RESULTS: Baseline MAP was significantly lower in the WKY rat group than in the SHR group. There was no significant difference in baseline CBF between the treated and the untreated groups. Following ceranapril administration, baseline MAP was reduced by 10 mmHg in WKY rats and by 20 mmHg in SHR, and the limits of CBF autoregulation were reset at lower blood pressure levels. In WKY rats as well as in SHR, ceranapril significantly reduced the lower blood pressure limit of CBF autoregulation. In both strains the upper limit of CBF autoregulation was reduced significantly.CONCLUSION: Ceranapril preserves CBF autoregulation and significantly shifts the limits of CBF autoregulation towards lower blood pressure values.
KW - Angiotensin-Converting Enzyme Inhibitors/pharmacology
KW - Animals
KW - Blood Pressure/drug effects
KW - Cerebrovascular Circulation/drug effects
KW - Homeostasis/drug effects
KW - Hypertension/drug therapy
KW - Male
KW - Organophosphorus Compounds/pharmacology
KW - Proline/analogs & derivatives
KW - Rats
KW - Rats, Inbred SHR
KW - Rats, Inbred WKY
KW - Time Factors
U2 - 10.1097/00004872-199304000-00010
DO - 10.1097/00004872-199304000-00010
M3 - Journal article
C2 - 8390507
VL - 11
SP - 399
EP - 405
JO - Journal of Hypertension, Supplement
JF - Journal of Hypertension, Supplement
SN - 0952-1178
IS - 4
ER -
ID: 279847685